What is CytoDyn Financial Strength?
CytoDyn has the Financial Strength Rank of 4.
Warning Sign:
CytoDyn Inc displays poor financial strength. Usually, this is caused by too much debt for the company.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
CytoDyn did not have earnings to cover the interest expense.
As of today, CytoDyn's Altman Z-Score is 0.00.
Competitive Comparison of CytoDyn's Financial Strength
For the Biotechnology subindustry, CytoDyn's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytoDyn's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CytoDyn's Financial Strength distribution charts can be found below:
* The bar in red indicates where CytoDyn's Financial Strength falls into.
CytoDyn Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
CytoDyn's Interest Expense for the
months ended in Feb. 2024 was $-1.56 Mil. Its Operating Income for the
months ended in Feb. 2024 was $-3.41 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was $0.18 Mil.
CytoDyn's Interest Coverage for the quarter that ended in Feb. 2024 is
| CytoDyn did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
CytoDyn's Debt to Revenue Ratio for the quarter that ended in Feb. 2024 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
CytoDyn has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytoDyn (CytoDyn) Business Description
Traded in Other Exchanges
Address
1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
CytoDyn Inc is a US-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The lead product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
Executives
| Tyler Blok |
officer: EVP of Legal Affairs |
1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660 |
| Stephen M Simes |
director |
|
| Ryan Dunlap |
director |
310 N. STATE STREET, SUITE 208, LAKE OSWEGO OR 97034 |
| Arvin Cyrus Arman |
officer: President |
1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660 |
| Karen J Brunke |
director |
1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660 |
| Tanya Durkee Urbach |
director |
1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660 |
| Lishomwa C Ndhlovu |
director |
1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660 |
| Harish Seethamraju |
director |
1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660 |
| Alan P Timmins |
director |
1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660 |
| Gordon A Gardiner |
director |
1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660 |
| Samir Rashmikant Patel |
director |
1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660 |
| Antonio Migliarese |
officer: Chief Financial Officer |
1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660 |
| Chris P Recknor |
officer: Chief Operating Officer |
1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660 |
| Michael D. Mulholland |
officer: CFO, Treasurer and Secretary |
1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660 |
| Jordan G Naydenov |
director |
1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660 |
CytoDyn (CytoDyn) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CYDY has been successfully added to your